SLC40A1 and iron metabolism disease: This effectively limits the applications of mammalian hepcidin mostly to the treatment of iron disorders, by targeting the hepcidin/ferroportin axis, since its use in infections would have a severe impact in several iron related parameters, with negative consequences to the host.